Send to

Choose Destination
Curr Pharm Biotechnol. 2011 Jun;12(6):884-96. doi: 1389-2010/11 $58.00+.00.

Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.

Author information

Molecular and Gene Therapy Program, Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, OH 45229, USA.


Mucopolysaccharidoses (MPS) are a group of lysosomal storage diseases that are resulted from abnormal accumulation of glycosaminoglycans. Among the progressive multi-organ abnormalities often associated with MPS diseases, the deterioration of central nervous system (CNS) is the most challenging manifestations to be tackled, due to the impermeability of the blood-brain-barrier (BBB). Evolved with recent development in stem cell biotechnology and gene therapy, several novel experimental approaches have been investigated in animal models. In this review, we will address different approaches attempting to bypass the BBB for neuropathic MPS treatment using cell- and gene-based therapies. Several neurological findings in CNS pathophysiology emerged with therapeutic investigation will also be discussed.

1389-2010/11 $58.00+.00
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd. Icon for PubMed Central
Loading ...
Support Center